idoxuridine
Trade name: herplex
Approved
Jun 11, 1963
Idoxuridine is an antiviral agent use in keratitis caused by herpes simplex virus. As a prescription drug it comes as a 0.1% ophthalmic solution/drops (Herplex and Dendrid). The first studies of the compound for treatment of human herpes simplex started in early 1960s. Being a structural analog of thymidine idoxuridine inhibits viral DNA replication by substituting thymidine. The effect of idoxuridine results in the inability of the virus to reproduce and/or infect tissues. Idoxuridine also blocks viral thymidine kinase as its substrate analog. — NCATS
Clinical trial activity
2 trials · 3 clinical orgs · 3 marketing orgs
Earliest trial started Mar 1, 1997 (NCT00109785)
Timeline
1960s
- Jun 11, 1963
Allergan — Earliest FDA Approval
- Jun 11, 1963
Allergan — NDA Secondary Org
- Jun 11, 1963
Allergan — NDA Organization
- Jun 28, 1963
Alcon — NDA Secondary Org
- Apr 6, 1964
GlaxoSmithKline — Marketing Organization
- Apr 6, 1964
GlaxoSmithKline — NDA Secondary Org
Indications
Approved for
Studied for
Mechanism of action
- DNAINHIBITOR
DNA inhibitor
Incorporation into DNA
Approval history
- approvedPriority reviewJun 11, 1963
Chemistry & pharmacology
SMILES
OC[C@H]1O[C@H](C[C@@H]1O)N2C=C(I)C(=O)NC2=O- Mol. weight
- 354.0985 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Topical
- Availability
- Discontinued
Oral
No
Parenteral
No
Topical
Yes
Sources
- WikipediaIdoxuridine ↗
- NCATSLGP81V5245 ↗
- ChEMBLCHEMBL788 ↗
Also known as
- 1-(2-deoxy-beta-d-ribofuranosyl)-5-iodouracil
- 1-(2-deoxy-beta-d-ribofuranosyl)-5-iodouracil
- 1-beta-d-2'-deoxyribofuranosyl-5-iodouracil
- 1-beta-d-2'-deoxyribofuranosyl-5-iodouracil
- 1beta-d-2'-deoxyribofuranosyl-5-iodouracil
- 1beta-d-2'-deoxyribofuranosyl-5-iodouracil
- 2'-deoxy-5-iodouridine
- 2'-deoxy-5-iodouridine
- 5-fluorodeoxyuridine
- 5-fluorodeoxyuridine
- 5-fluorodeoxyuridine
- (+)-5-iodo-2'-deoxyuridine
- (+)-5-iodo-2'-deoxyuridine
- 5-iodo-2'-deoxyuridine
- 5-iodo-2'-deoxyuridine
- 5-iododeoxyuridine
- 5-iododeoxyuridine
- 5-iodouracil deoxyriboside
- 5-iodouracil deoxyriboside
- 5iudr
- 5iudr
- allergan
- allergan 211
- allergan 211
- allergan-211
- allergan-211
- dendrid
- dendrid
- herplex
- herplex
- idox
- idoxene
- idoxuridin
- idoxuridin
- idoxuridin
- idoxuridina
- idoxuridina
- idoxuridine
- idoxuridine
- idoxuridine
- idoxuridine
- idoxuridine
- idoxuridine
- idoxuridine
- idoxuridine
- idoxuridine
- idoxuridine
- idoxuridine
- idoxuridinum
- idoxuridinum
- idu
- idu
- idu
- iododeoxyridine
- iododeoxyridine
- iododeoxyuridine
- iododeoxyuridine
- iododeoxyuridine
- iodoxuridine
- iodoxuridine
- joddeoxiuridin
- joddeoxiuridin
- kerecid
- kerecid
- ophthalmadine
- ophthalmadine
- sk&f-14287
- sk&f-14287
- stoxil
- stoxil
- stoxil
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00003405 | Phase 2 | Apr 1, 1998 | National Cancer Institute (NCI), Rush University |
| NCT00109785 | Phase 1 | Mar 1, 1997 | Cornell University, National Cancer Institute (NCI) |
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 2 | 0 | 2 | 1997 |
| Cornell University | Academic/Hospital | 1 | 1 | 1 | 1997 |
| Rush University | Academic/Hospital | 1 | 1 | 1 | 1998 |
Marketing (5)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Alcon | For profit | NDA2 | Jun 28, 1963 |
| Allergan | For profit | NDA2 | Jun 11, 1963 |
| Allergan | For profit | NDA | Jun 11, 1963 |
| GlaxoSmithKline | For profit | MKTG | Apr 6, 1964 |
| GlaxoSmithKline | For profit | NDA2 | Apr 6, 1964 |